One important metric to look for in a stock is an 80 or higher Relative Strength Rating. BioAge Labs just hit that mark, with a jump from 71 to 85 Monday.
This proprietary rating identifies technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks matches up against that of all other stocks.
Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 as they launch their biggest runs.
Hone Your Stock-Picking Skills By Focusing On These Factors
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to form a chart pattern and break out.
BioAge Labs reported 0% EPS growth in its most recent report. Sales rose 0%.
BioAge Labs earns the No. 225 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
